To compare efficacy and safety of the dopamine agonist pramipexole (PPX) versus reference treatment with dual release levodopa/benserazide (L/B) in de novo patients with restless legs syndrome (RLS)
The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and...
BACKGROUND: Pramipexole is a D3 dopaminergic agonist that has shown a major effect on both sensory ...
Although various drugs are currently used for restless legs syndrome (RLS) in clinic, selecting appr...
QUESTIONS UNDER STUDY: To compare efficacy and safety of the dopamine agonist pramipexole (PPX) vers...
Pramipexole is a non-ergoline dopamine agonist with a high selectivity for D2 and D2 receptors. Init...
Restless Legs Syndrome (RLS) is one of the most common neurological diseases characterized by an urg...
Wei Zhang, Ye Wang, Shu Yan Cong, Jian Fei Nao, Juan Feng, Guo Rong Bi Neurology Department, Shengji...
Francesca Brindani, Francesca Vitetta, Franco GemignaniDepartment of Neurosciences, University of Pa...
Dopamine agonists, particularly nonergot dopamine agonists such as pramipexole, have become the main...
Dopamine agonists, particularly nonergot dopamine agonists such as pramipexole, have become the main...
1. Describe the epidemiology, pathophysiology and diagnostic criteria for restless legs syndrome (RL...
IntroductionRestless legs syndrome (RLS) is a common neurological sensorimotor disorder among patien...
The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and...
The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and...
The use of levodopa, a drug commonly used to treat symptoms of Parkinson's disease, in the managemen...
The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and...
BACKGROUND: Pramipexole is a D3 dopaminergic agonist that has shown a major effect on both sensory ...
Although various drugs are currently used for restless legs syndrome (RLS) in clinic, selecting appr...
QUESTIONS UNDER STUDY: To compare efficacy and safety of the dopamine agonist pramipexole (PPX) vers...
Pramipexole is a non-ergoline dopamine agonist with a high selectivity for D2 and D2 receptors. Init...
Restless Legs Syndrome (RLS) is one of the most common neurological diseases characterized by an urg...
Wei Zhang, Ye Wang, Shu Yan Cong, Jian Fei Nao, Juan Feng, Guo Rong Bi Neurology Department, Shengji...
Francesca Brindani, Francesca Vitetta, Franco GemignaniDepartment of Neurosciences, University of Pa...
Dopamine agonists, particularly nonergot dopamine agonists such as pramipexole, have become the main...
Dopamine agonists, particularly nonergot dopamine agonists such as pramipexole, have become the main...
1. Describe the epidemiology, pathophysiology and diagnostic criteria for restless legs syndrome (RL...
IntroductionRestless legs syndrome (RLS) is a common neurological sensorimotor disorder among patien...
The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and...
The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and...
The use of levodopa, a drug commonly used to treat symptoms of Parkinson's disease, in the managemen...
The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and...
BACKGROUND: Pramipexole is a D3 dopaminergic agonist that has shown a major effect on both sensory ...
Although various drugs are currently used for restless legs syndrome (RLS) in clinic, selecting appr...
DOI
Add to ORKG